The 2025-26 Pfizer COVID-19 vaccine is about 57% effective against emergency department/urgent care (ED/UC) visits and 54% effective against outpatient visits among adults roughly 4 weeks after vaccination, with considerable uncertainty, according to preliminary estimates published on the preprint server medRxiv.

Sales of Pfizer’s PFE COVID products, Comirnaty and Paxlovid, declined from their peak with the end of the pandemic. Their sales came down to around $11 billion in 2024 and $6.7 billion in 2025 from $56.

Add Yahoo as a preferred source to see more of our stories on Google. The Pfizer Covid vaccine increased the risk of heart problems for children sixfold in the first week of having the jab but led to fewer cases in the long term, research suggests.

A Brussels court is weighing whether Poland must pay Pfizer €1.4 billion for undelivered COVID vaccines, in a case that could impact future EU crisis procurement deals

Sanofi was criticized by a U.K. trade group, which accused it of making misleading claims about its RSV vaccine and disparaging a rival product from Pfizer.

Learn about the safety and effectiveness of COVID-19 vaccines for kids, the possible side effects, and the benefits of vaccination.